Skip to main content
SINT logo

SINT · Sintx Technologies, Inc. · Documents

Track SINT — free
$1.35 -0.20 (-12.66%) At close · Nov 13 Play latest call Q2 2026 earnings call transcript
Market Cap
$10.17M
Shares
7.56M
Volume · Nov 13 77.62K Avg daily vol (3M) 49.39K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $1.02M down 64.7% 10-K filed Mar 20, 2026 Quarterly report FY2026 Q3 Revenue $2.19M up 952.9% 10-Q filed Nov 5, 2026 Latest results Revenue surged as losses narrowed 8-K filed Nov 5, 2026 Earnings call Q2 2026 earnings call Held Aug 11, 2026
2026
Nov 5
Current report 8-K
Revenue surged as losses narrowed

SINTX Technologies, Inc. reported third-quarter revenue of approximately $2.2 million versus $208,000, net loss of approximately $1.6 million, down 55%, and completed the limited-use release of the FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System.

Financial results, Regulation FD disclosure
4 source passages
SALT LAKE CITY, Utah – November 5, 2026 – SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a global leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today announced its financial results and business highlights for the third quarter ended September 30, 2026. For the three months ended September 30, 2026, total revenue increased to approximately $2.2 million, compared with $208,000 during the prior-year period Net loss decreased 55% to approximately $1.6 million, compared with $3.5 million during the prior-year quarter Completed the limited-use release of the FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System, initiated in the first quarter of 2026 Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises 315%, but going-concern doubt remains

SINTX Technologies reported total revenue growth of 315% for the nine months ended September 30, 2026, while net loss was $7.1 million and operating cash use was $6.6 million; substantial doubt remains about its ability to continue as a going concern.

Revenue $2.19M ▲ 952.9% Net loss $1.6M Diluted EPS -$0.24
Read from the MD&A section
4 source passages
SINTX Technologies is an advanced ceramics company formed in December 1996 that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. For the nine months ended September 30, 2026, total revenue increased $2.3 million, or 315%, compared to the same period in 2025. For the nine months ended September 30, 2026 and 2025, we incurred net losses of $7.1 million and $8.1 million, respectively, and used cash in operating activities of $6.6 million and $6.2 million, respectively. Management has concluded that substantial doubt remains regarding our ability to continue as a going concern for a period of one year from the date these condensed consolidated financial statements are issued. Open the document at this passage
Oct 30
Proxy statement DEF 14A
Proxy statement

SINTX Technologies, Inc. will hold its annual meeting on December 9, 2026, to elect Mark Anderson and Gregg Honigblum as Class III directors through 2029, ratify Tanner LLP, approve advisory executive compensation, and authorize possible adjournments.

Read from the first part of this long document
Oct 9
Current report 8-K Events of Oct 8
Other events

SINTX Technologies, Inc. received $2,014,645.22 from funded exercises and related exchanges involving 941,423 Class B warrant shares at $2.14 per share, issued 651,204 common shares and pre-funded warrants for 290,219 shares, and ended with no Class B warrants outstanding.

Oct 1
Current report 8-K
Financial results, Regulation FD disclosure

SINTX Technologies, Inc. reported preliminary, unaudited revenue of $2.2 million for the quarter ended September 30, 2026, including approximately $2.1 million in product sales. It intends to call Class B Warrants covering approximately 1.88 million shares.

Aug 11
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $452K ▲ 199.3% Net loss $2.71M Diluted EPS -$0.75
May 15
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $380K ▲ 3.0% Net loss $2.82M Diluted EPS -$0.70
Mar 20
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $1.02M ▼ 64.7% Net loss $10.36M Diluted EPS -$6.16
2025
Mar 19
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $2.89M ▲ 9.9% Net loss $11.02M Diluted EPS -$15.19
2024
Showing 1–50 of 157 documents
Key facts CIK 1269026 CUSIP 829392703 13F (30d) 25 filings 16 filers Visit website Investor relations